Two is better than one: drug synergy in relapsed/refractory NHL
Paul A. Hamlin
Potential second-line treatment for indolent lymphoma
Precision medicine for MDS, what drugs for which patients?
The IFM 2012-03 trial: what will the next step be?
Encouraging data from the RAY trial 3-year follow-up